Sensulin is a drug-discovery company organized around developing a once-a-day, glucose-responsive insulin that may be able to mimic the human pancreas and treat diabetes, potentiallyeliminating the need for basal and prenadial insulin treatments. Agglomerated Vesicle Technology - the firm's drug delivery platform - is based upon a series of liposomes that are linked by a stimulus-responsive molecule, which can be used to encapsulate various drugs that are triggered by a variety of stimuli. The firm focuses on developing glucose-responsive insulin that may mimic a healthy human pancreas primarily for type I and type II diabetes.
